Coya Therapeutics, Inc. (NASDAQ:COYA) Expected to Earn FY2025 Earnings of ($1.26) Per Share

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities research analysts at Chardan Capital issued their FY2025 EPS estimates for Coya Therapeutics in a report issued on Tuesday, August 13th. Chardan Capital analyst K. Nakae forecasts that the company will post earnings of ($1.26) per share for the year. Chardan Capital has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.30) per share.

Separately, Rodman & Renshaw began coverage on Coya Therapeutics in a research note on Thursday, June 13th. They issued a “buy” rating and a $18.00 price target on the stock.

Coya Therapeutics Trading Up 2.2 %

NASDAQ COYA opened at $5.12 on Thursday. The firm has a market cap of $74.84 million, a PE ratio of -6.02 and a beta of 0.59. Coya Therapeutics has a 1-year low of $3.21 and a 1-year high of $10.69. The stock has a 50-day moving average of $6.57 and a 200-day moving average of $7.80.

Institutional Investors Weigh In On Coya Therapeutics

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new stake in shares of Coya Therapeutics during the second quarter worth about $101,000. Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics in the 2nd quarter worth approximately $61,000. Vanguard Group Inc. grew its position in shares of Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. Greenlight Capital Inc. increased its stake in shares of Coya Therapeutics by 172.2% during the fourth quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after buying an additional 805,959 shares during the period. Finally, AIGH Capital Management LLC increased its stake in shares of Coya Therapeutics by 92.6% during the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after buying an additional 496,183 shares during the period. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.